

CSD/BSE/NSE/2022-2023
January 16, 2023

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Credit Rating

.....

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on January 16, 2023.

Facilities	Rating
Long-term Bank Facilities	CRISIL A+/Watch Developing (Placed on 'Rating Watch with Developing Implications')
Short-term Bank Facilities	CRISIL A1+/Watch Developing (Placed on 'Rating Watch with Developing Implications')

This is for your information and record.

Thanking you,
Yours faithfully,
For Suven Pharmaceuticals Limited

K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5
Avenue 7 | Banjara Hills | Hyderabad - 500034 | Telangana | India | CIN: L24299TG2018PLC128171
Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com